Daisuke Muraoka

Daisuke Muraoka

Auto-generated profile, based on publicly available information

Daisuke Muraoka

Division of Translational Oncoimmunology, Aichi Cancer Center Research Institute, Nagoya, Japan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2022 in Journal of Controlled Release
Verified
Journal Article
Closed access
DMDaisuke Muraoka
Daisuke Muraoka
NHNaozumi Harada
Naozumi Harada
HSHiroshi Shiku
Hiroshi Shiku
KAKazunari Akiyoshi
Kazunari Akiyoshi

3 February 2022 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
YDYosuke Dotsu
Yosuke Dotsu
DMDaisuke Muraoka
Daisuke Muraoka
NONaohisa Ogo
Naohisa Ogo
YSYudai Sonoda
Yudai Sonoda
KYKiyoshi Yasui
Kiyoshi Yasui
HIHiroaki Ikeda
Hiroaki Ikeda
Background Cancer immunotherapy shows insufficient efficacy for low immunogenic tumors. Furthermore, tumors often downregulate antigen and major histocompatibility complex expression to escape recognition by T cells, resulting in insufficient T cell receptor (TCR) stimulation in the tumor microenvironment. Thus, augmenting TCR-mediated recognition of tumor antigens is a useful strategy to improve the efficacy of cancer immunotherapy. Methods We screened 310 small molecules from our library and identified PQDN, a small molecule that activates CD8 T cells after TCR engagement, even when antigen stimulation is too weak for their activation. We used inhibitors of mitochondrial functions and Seahorse Flux Analyzer to investigate the mechanism underlying the effect of PQDN on T cells. Effect of PQDN on tumor-infiltrating CD8 T cells was examined using flow cytometry and TCR repertoire analysis. Results PQDN increased mitochondrial reciprocal capacity through enhancement of electron transport chains (ETCs) and facilitated glycolysis via mTOR/AKT signaling, resulting in augmented CD8 T cell activation, even when antigen stimulation is extremely weak. Intratumoral administration of this compound into tumor-bearing mice tunes inactivated T cell with tumor antigen recognition potent and expanded functional T cell receptor diversity of tumor-infiltrating T cells, augmenting antitumor immune responses and retarding tumor growth. Furthermore, PQDN has a synergistic potent with T cell dependent immunotherapy, such as checkpoint inhibitory therapy or adoptive cell therapy, even in a low immunogenic tumor. We also demonstrated that this compound enhances the activation of human CD8 T cells. Conclusions These data suggest that tuning the T cell activation threshold by chemical activation of mitochondrial ETC is a new strategy for improving therapeutic efficacy through the activation of low-avidity tumor-specific T cells.

7 September 2023 in Cancer Science
Verified
Journal Article
Open access
SOSatomi Okada
Satomi Okada
DMDaisuke Muraoka
Daisuke Muraoka
KYKiyoshi Yasui
Kiyoshi Yasui
ITIsao Tawara
Isao Tawara
AKAyumi Kawamura
Ayumi Kawamura
HIHiroaki Ikeda
Hiroaki Ikeda
Adoptive immunotherapy using genetically engineered patient‐derived lymphocytes to express tumor‐reactive receptors is a promising treatment for malignancy. However, utilization of autologous T cells in this therapy limits the quality of gene‐engineered T cells, thereby inhibiting the timely infusion of the cells into patients. In this study, we evaluated the anti‐tumor efficacy and the potential to induce graft‐versus‐host disease (GVHD) in T cell receptor (TCR) gene‐engineered allogeneic T cells that downregulate the endogenous TCR and HLA class I molecules with the aim of developing an “off‐the‐shelf” cell product with expanded application of genetically engineered T cells. We transduced human lymphocytes with a high‐affinity TCR specific to the cancer/testis antigen NY‐ESO‐1 using a novel retrovirus vector with siRNAs specific to the endogenous TCR (siTCR vector). These T cells showed reduced expression of endogenous TCR and minimized reactivity to allogeneic cells in vitro. In non‐obese diabetic/SCID/γcnull mice, TCR gene‐transduced T cells induced tumor regression without development of GVHD. A lentivirus‐based CRISPR/Cas9 system targeting β‐2 microglobulin in TCR gene‐modified T cells silenced the HLA class I expression and prevented allogeneic CD8+ T cell stimulation without disrupting their anti‐tumor capacity. This report is the first demonstration that siTCR technology is effective in preventing GVHD. Adoptive cell therapy with allogeneic T cells engineered with siTCR vector may be useful in developing an “off‐the‐shelf” therapy for patients with malignancy.

18 September 2024 in npj Vaccines
Verified
Journal Article
Open access
PDF file
DMDaisuke Muraoka
Daisuke Muraoka
Meng Ling MoiMeng Ling Moi
Meng Ling Moi
OMOsamu Muto
Osamu Muto
TNTakaaki Nakatsukasa
Takaaki Nakatsukasa
SDSituo Deng
Situo Deng
NHNaozumi Harada
Naozumi Harada
Vaccine-induced T cells and neutralizing antibodies are essential for protection against SARS-CoV-2. Previously, we demonstrated that an antigen delivery system, pullulan nanogel (PNG), delivers vaccine antigen to lymph node medullary macrophages and thereby enhances the induction of specific CD8+ T cells. In this study, we revealed that medullary macrophage-selective delivery by PNG depends on its binding to a C-type lectin SIGN-R1. In a K18-hACE2 mouse model of SARS-CoV-2 infection, vaccination with a PNG-encapsulated receptor-binding domain of spike protein decreased the viral load and prolonged the survival in the CD8+ T cell- and B cell-dependent manners. T cell receptor repertoire analysis revealed that although the vaccine induced T cells at various frequencies, low-frequency specific T cells mainly promoted virus clearance. Thus, the induction of specific CD8+ T cells that respond quickly to viral infection, even at low frequencies, is important for vaccine efficacy and can be achieved by SIGN-R1+ medullary macrophage-targeted antigen delivery.

17 March 2025 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
TNTakaaki Nakatsukasa
Takaaki Nakatsukasa
DMDaisuke Muraoka
Daisuke Muraoka
SDSituo Deng
Situo Deng
KYKiyoshi Yasui
Kiyoshi Yasui
SSShin-Ichi Sawada
Shin-Ichi Sawada
HIHiroaki Ikeda
Hiroaki Ikeda
Many cancer patients develop resistance to immunotherapy, highlighting the urgent need for novel therapeutic strategies. Various factors contribute to tumor resistance to immunotherapy, among which tumor-associated macrophages (TAMs) are critical regulators of tumor sensitivity. Therefore, combining cancer immunotherapies with drug delivery systems (DDSs) targeting TAMs has become an intriguing treatment strategy. However, the target molecules used in DDSs are limited to a few receptors expressed on TAMs. Therefore, the identification of novel target molecules for TAM-specific DDS is urgently needed. The current study evaluated the ability of a cholesteryl pullulan (CHP) nanogel to target TAMs via mDC-SIGN (CD209b). This nanogel encapsulated the cytotoxic protein drug Pseudomonas exotoxin A and was injected into a tumor-bearing mouse model. This treatment significantly reduced the abundance of CD209b-positive M2 TAMs and enhanced antitumor immune responses. Ultimately, tumor growth was suppressed, even in a low-immunogenic tumor model. Hence, CD209b is an effective target molecule for M2 TAM-specific DDSs that can be used to develop novel cancer therapies.

3 February 2026 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YSYujia Sun
Yujia Sun
ADAyako Demachi-Okamura
Ayako Demachi-Okamura
SSShuichi Shinohara
Shuichi Shinohara
YWYizheng Wang
Yizheng Wang
ZGZhongliang Guo
Zhongliang Guo
DMDaisuke Muraoka
Daisuke Muraoka